Wall Street analysts forecast that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report $1.04 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Vertex Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.98 and the highest estimate coming in at $1.12. Vertex Pharmaceuticals reported earnings per share of $0.94 in the same quarter last year, which indicates a positive year over year growth rate of 10.6%. The business is scheduled to issue its next quarterly earnings results on Wednesday, July 24th.
According to Zacks, analysts expect that Vertex Pharmaceuticals will report full year earnings of $4.22 per share for the current financial year, with EPS estimates ranging from $4.07 to $4.58. For the next fiscal year, analysts expect that the company will report earnings of $5.79 per share, with EPS estimates ranging from $5.08 to $6.32. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Vertex Pharmaceuticals.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.49. The company had revenue of $857.00 million during the quarter, compared to analysts’ expectations of $853.00 million. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The firm’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.76 earnings per share.
In related news, SVP Paul M. Silva sold 161 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $165.41, for a total transaction of $26,631.01. Following the completion of the transaction, the senior vice president now directly owns 17,759 shares in the company, valued at $2,937,516.19. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Stuart A. Arbuckle sold 5,624 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $181.75, for a total value of $1,022,162.00. Following the transaction, the executive vice president now owns 36,272 shares of the company’s stock, valued at $6,592,436. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 165,399 shares of company stock valued at $28,980,388. 0.70% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP lifted its stake in Vertex Pharmaceuticals by 1.1% during the first quarter. Marshall Wace LLP now owns 62,232 shares of the pharmaceutical company’s stock worth $11,447,000 after purchasing an additional 672 shares during the last quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund bought a new stake in Vertex Pharmaceuticals during the first quarter worth about $533,000. Nordea Investment Management AB lifted its stake in Vertex Pharmaceuticals by 239.3% during the first quarter. Nordea Investment Management AB now owns 46,959 shares of the pharmaceutical company’s stock worth $8,638,000 after purchasing an additional 33,119 shares during the last quarter. Horizon Investments LLC bought a new stake in Vertex Pharmaceuticals during the first quarter worth about $245,000. Finally, FMR LLC lifted its stake in Vertex Pharmaceuticals by 19.3% during the first quarter. FMR LLC now owns 24,434,159 shares of the pharmaceutical company’s stock worth $4,494,663,000 after purchasing an additional 3,951,050 shares during the last quarter. Institutional investors and hedge funds own 94.94% of the company’s stock.
Shares of NASDAQ VRTX opened at $173.51 on Wednesday. The firm has a market capitalization of $44.38 billion, a PE ratio of 61.31, a P/E/G ratio of 2.51 and a beta of 1.48. Vertex Pharmaceuticals has a fifty-two week low of $145.37 and a fifty-two week high of $195.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.66.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Read More: What is a back-end load?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.